Further, we report that the combined inhibition of Mcl-1 using VU661013 with blockade of Bcl-2/Bcl-xL using ABT-263 resulted in superior tumor cell killing and tumor growth inhibition in ERα+ breast cancers in culture and in vivo. Here, BCL2L1 is linked to breast cancer.